Sagimet Biosciences Files 8-K for Compliance, Nasdaq Listing Confirmed

Ticker: SGMT · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1400118

Complexity: simple

Sentiment: neutral

Topics: compliance, corporate-governance, regulatory-filing

TL;DR

**Sagimet Biosciences filed a routine 8-K, mostly for compliance and confirming their Nasdaq listing.**

AI Summary

Sagimet Biosciences Inc. filed an 8-K on January 22, 2024, primarily to satisfy filing obligations related to written communications under Rule 425 of the Securities Act. This filing updates their corporate information, including their address at 155 Bovet Road, Suite 303, San Mateo, California, and confirms their Series A Common Stock is registered on Nasdaq under the symbol SGMT. For investors, this filing is largely administrative, indicating no immediate operational or financial changes, but it ensures compliance and transparency regarding their registered securities.

Why It Matters

This filing is mainly administrative, confirming Sagimet Biosciences' compliance with SEC regulations and the listing of its Series A Common Stock on Nasdaq, which is important for maintaining investor confidence and market access.

Risk Assessment

Risk Level: low — This 8-K filing is administrative and does not disclose any new financial or operational risks for Sagimet Biosciences Inc.

Analyst Insight

Investors should view this filing as a routine administrative update, confirming compliance and listing details. It does not provide new information that would warrant immediate buying or selling decisions, but rather reinforces the company's status as a publicly traded entity on Nasdaq.

Key Players & Entities

FAQ

What is the primary purpose of Sagimet Biosciences Inc.'s 8-K filing dated January 22, 2024?

The primary purpose of Sagimet Biosciences Inc.'s 8-K filing dated January 22, 2024, is to satisfy the filing obligation of the registrant under written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

What is the current business address of Sagimet Biosciences Inc. as stated in the filing?

The current business address of Sagimet Biosciences Inc. is 155 Bovet Road, Suite 303, San Mateo, California 94402.

What is the trade symbol and the exchange where Sagimet Biosciences Inc.'s securities are registered?

The trade symbol for Sagimet Biosciences Inc.'s Series A Common Stock is SGMT, and it is registered on The Nasdaq Stock Market.

Has Sagimet Biosciences Inc. changed its name since its last report, according to this filing?

No, the filing states 'Not Applicable' for 'Former Name or Former Address, if Changed Since Last Report', indicating no change in name since the last report. However, the company was formerly known as 3-V Biosciences, Inc. with a name change date of 20070521, which is historical information from the filer data, not a recent change.

What is the Commission File Number for Sagimet Biosciences Inc.?

The Commission File Number for Sagimet Biosciences Inc. is 001-41742.

Filing Stats: 676 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-01-22 08:00:39

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 22, 2024, Sagimet Biosciences Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On January 22, 2024, the Company issued a press release announcing positive topline results from its Phase 2b FASCINATE-2 clinical trial of denifanstat in biopsy-confirmed F2/F3 non-alcoholic steatohepatitis (NASH) patients. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. As described in the press release, representatives of the Company will host a live webcast to discuss the results from this clinical trial at 8:00 a.m. ET on January 22, 2024. A copy of the presentation to be used during the webcast is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated January 22, 2024. 99.2 Press Release of Sagimet Biosciences Inc., dated January 22, 2024. 99.3 Sagimet Biosciences Announces Topline Results from Phase 2b FASCINATE-2 Clinical Trial. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: January 22, 2024 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing